Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.
Atherothrombotic vascular disease continues to be a leading cause of morbidity and mortality in much of the world. Although a healthy lifestyle and low-density lipoprotein cholesterol lowering significantly reduce cardiovascular morbidity and mortality, substantial number of adverse vasoocclusive events continue to occur. These realities have brought attention to additional therapies that could further reduce cardiovascular events. High-density lipoprotein (HDL)/apolipoprotein A-I (apo A-I)-based therapies are a potential therapeutic strategy against atherothrombotic vascular disease because of the known inverse relationship between HDL cholesterol and coronary heart disease, favorable and pleotrophic biologic effects of HDL/apo A-I, results of preclinical experimental studies, and emerging proof of concept in clinical studies. A variety of HDL/apo A-I-based therapies are currently under investigation, including synthetic peptides that mimic the function of HDL. Such apo A-I mimetic peptides are the focus of this review.
Shah
Prediman K
PK
Atherosclerosis Research Center, Division of Cardiology, Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. shahp@cshs.org
Chyu
Kuang-Yuh
KY
D000818:Animals; D016632:Apolipoprotein A-I / Q000502:physiology*; D050197:Atherosclerosis / Q000503:physiopathology*; D006801:Humans; D008075:Lipoproteins, HDL / Q000502:physiology; D010455:Peptides / Q000008:administration & dosage / Q000502:physiology*
D016632:Apolipoprotein A-I; C465468:D-4F peptide; D008075:Lipoproteins, HDL; D010455:Peptides